Iv%2520dexamethasone

# IV Dexamethasone ## Overview Dexamethasone is a potent, long-acting synthetic glucocorticoid with minimal mineralocorticoid activity. It possesses profound anti-inflammatory and immunosuppressive properties. It has a long biological half-life (36–72 hours). ## Primary Indications * Cerebral edema (associated with brain tumors, neurosurgery) * Severe allergic reactions (anaphylaxis adjuvant) * Acute exacerbations of COPD/Asthma * Antiemetic prophylaxis (chemotherapy-induced nausea and vomiting) * Bacterial meningitis (adjuvant to reduce neurological sequelae) * COVID-19 (in patients requiring supplemental oxygen) ## Adult Dosing * **Cerebral Edema:** Loading dose 10 mg IV, followed by 4 mg IM/IV every 6 hours. * **Anti-inflammatory/Immunosuppressive:** 0.75 mg to 9 mg daily, depending on severity. * **COVID-19:** 6 mg IV once daily for up to 10 days. * **Antiemetic (CINV):** 10–20 mg IV once before chemotherapy. * **Bacterial Meningitis:** 10 mg IV every 6 hours for 4 days (ideally given with or before the first antibiotic dose). ## Pediatric Dosing * **Bacterial Meningitis:** 0.15 mg/kg per dose every 6 hours for 4 days (start with/before first antibiotic dose). * **Croup:** 0.6 mg/kg (max 10 mg) as a one-time dose. * **Cerebral Edema (Loading):** 1–2 mg/kg IV once, followed by 1–1.5 mg/kg/day divided every 4–6 hours (max dose usually 16 mg/day, but varies by protocol). * *Note: Always verify pediatric dosing against weight-based institutional protocols.* ## Dose Adjustments * **Hepatic Impairment:** Clearance may be decreased; monitor for toxicity. * **Severe Infections:** May require higher doses; assess risk-benefit ratio. * **Tapering:** Long-term use (>1–2 weeks) requires a gradual taper to prevent HPA-axis suppression. ## Contraindications * Systemic fungal infections. * Known hypersensitivity to dexamethasone or components. * Administration of live or live-attenuated vaccines while on immunosuppressive doses. ## Adverse Effects * **Endocrine:** Hyperglycemia/diabetes mellitus, HPA-axis suppression, Cushing’s syndrome. * **Gastrointestinal:** Peptic ulcer disease, GI hemorrhage (especially if combined with NSAIDs). * **Neurological:** Insomnia, mood swings, psychosis, anxiety. * **Musculoskeletal:** Myopathy, delayed wound healing, osteoporosis. * **Infection:** Increased susceptibility to secondary infections. ## Key Drug Interactions * **NSAIDs/Aspirin:** Increased risk of GI ulceration and bleeding. * **CYP3A4 Inducers (e.g., Phenytoin, Rifampin, Carbamazepine):** Decrease dexamethasone efficacy; may require dose increase. * **Antidiabetic Agents:** Dexamethasone antagonizes hypoglycemic effects; glycemic control may worsen. * **Warfarin:** Variable effects; monitor INR closely. ## Monitoring * Blood glucose (frequent monitoring in diabetic patients). * Blood pressure. * Electrolytes (hypokalemia). * Signs of active infection or GI bleeding. * Neuropsychiatric symptoms. ## Clinical Pearls * **Administration:** May be given slow IV push over 1–5 minutes or as an infusion. * **Rapid Withdrawal:** Avoid sudden discontinuation after long-term use to prevent acute adrenal crisis. * **Timing:** For bacterial meningitis, failure to administer dexamethasone prior to or concurrently with the first dose of antibiotics significantly reduces its clinical efficacy. * **Local Protocols:** Significant variability exists in dosing for septic shock, COVID-19, and neuro-oncology; always consult your facility’s specific clinical pathways. *** **Educational Disclaimer:** This information is intended for educational purposes for healthcare professionals and does not constitute medical advice. Always verify current prescribing information, institutional protocols, and patient-specific factors before administering any medication.